J. Randolph Hecht, MD, discusses the challenges researchers have faced in the development of cellular therapy for patients with solid tumors, and details how A2B530 could potentially overcome some of these obstacles.
Megan Hollasch
Advertisement
Articles by Megan Hollasch
Marwan G. Fakih, MD, discusses how the BASECAMP-1 and EVEREST-1 trials will work in concert, diving into the unique mechanism of action of A2B530.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CGTlive®
1
PreBLA Meeting With FDA Sinks uniQure’s Hopes for Approval of Huntington Disease Gene Therapy AMT-130 Based Primarily on Phase 1/2 Data
2
FDA Activity Recap: October 2025 Features New Platform Technology Designation, RDEA Pilot Program Selection, and More
3
